At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 468 enrolled
Drug / intervention
Reslizumab +1 moredrug
Likely dose
Reslizumab 110 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted May 22, 2015·Updated Nov 9, 2021
In Brief
A Phase 3 clinical trial evaluating Reslizumab and Placebo for Asthma. Completed, enrolled 468 participants across 226 sites in 21 countries.
Detailed Summary
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Japan, Mexico, New Zealand, Poland, Romania, Russia, South Africa, South Korea, Spain, Turkey (Türkiye), Ukraine, United States
CollaboratorsPPD Development, LP
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartSep 2015
Primary CompletionDec 2017
Study CompletionJan 2018
TodayJul 2026
First PostedMay 22, 2015
Enrollment StartSep 28, 2015
Primary CompletionDec 4, 2017
Study CompletionJan 31, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.1 years ago
Interventions
Reslizumabdrug
Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
Placebodrug
Matching Placebo